Key result
TPO mutagenesis identifies 10 residues essential for bioactivity, with the R10A mutant lacking proliferative activity.
Why the study?
The functional importance of specific residues in thrombopoietin for receptor binding and bioactivity was not fully understood.
Specific residues in helices A and D of thrombopoietin are critical for c-Mpl receptor interaction and subsequent cell proliferation.
Answers are grounded in this paper and cite their sources.
May guide TPO mimetic design; leaves open clinical translation in humans.
Thrombopoietin (TPO) is a haematopoietic growth factor responsible for megakaryocyte progenitor proliferation and differentiation. It belongs to the four-helix-bundle cytokine family and exerts its biological effects through binding to a specific receptor, c-Mpl. With the use of site-directed mutagenesis we have generated 20 TPO mutants. Each of the TPO mutants was produced in a eukaryotic expression system and the mutants' ability to induce the proliferation of factor-dependent c-Mpl-expressing megakaryoblastic M-O7e cells was compared with that of wild-type TPO. Among the mutations studied, 10 lead to a significant decrease in TPO bioactivity. Of these ten residues, three are located in helix A of the protein (Arg10, Lys14 and Arg17) and four in helix D (His133, Gln132, Lys138 and Phe141), indicating that in TPO, as in other cytokines, these two helices are important for functional cytokine/receptor interactions. Surprisingly, mutant Arg10-->Ala (R10A) lacked any proliferative activity, despite the fact that this mutation was recently reported to have no effect on TPO/c-Mpl binding in a TPO phage ELISA [Pearce, Potts, Presta, Bald, Fendly and Wells (1997) J. Biol. Chem. 272, 20595-20602]. The lack of M-O7e proliferation is probably due to an inability of R10A mutant to promote receptor dimerization and thus receptor activation. Moreover we found that the Arg10 and Arg17 residues of TPO seem to be specific determinants for TPO/c-Mpl recognition. We also demonstrate that the O-glycosylation site located at position 110 of TPO is not necessary for the bioactivity of the cytokine.
No takes yet. Share an insight, caveat, or question.
Jagerschmidt et al. (1998) studied this question. TPO mutants vs. Wild-type TPO was evaluated on Proliferation of factor-dependent c-Mpl-expressing megakaryoblastic M-O7e cells. Site-directed mutagenesis of thrombopoietin identified 10 residues in helices A and D essential for bioactivity, with the R10A mutant lacking proliferative activity.
Synapse has enriched 10 related papers. Consider them for comparative context: